Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
L Ghosn, R Assi, T Evrenoglou… - Cochrane database …, 2023 - cochranelibrary.com
Cochrane database of systematic reviews, 2023•cochranelibrary.com
Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm
responsible for severe respiratory symptoms. Since interleukin 6 (IL‐6) is one of the
cytokines released during this inflammatory process, IL‐6 blocking agents have been used
for treating people with severe COVID‐19. Objectives To update the evidence on the
effectiveness and safety of IL‐6 blocking agents compared to standard care alone or to a …
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm
responsible for severe respiratory symptoms. Since interleukin 6 (IL‐6) is one of the
cytokines released during this inflammatory process, IL‐6 blocking agents have been used
for treating people with severe COVID‐19. Objectives To update the evidence on the
effectiveness and safety of IL‐6 blocking agents compared to standard care alone or to a …
Abstract
Background
It has been reported that people with COVID‐19 and pre‐existing autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm responsible for severe respiratory symptoms. Since interleukin 6 (IL‐6) is one of the cytokines released during this inflammatory process, IL‐6 blocking agents have been used for treating people with severe COVID‐19.
Objectives
To update the evidence on the effectiveness and safety of IL‐6 blocking agents compared to standard care alone or to a placebo for people with COVID‐19.
cochranelibrary.com